Analysis of U.S. Patent 3,700,681: Scope, Claims, and Patent Landscape
What is the Scope and Content of U.S. Patent 3,700,681?
U.S. Patent 3,700,681 was issued to Pfizer Inc. on October 24, 1972. It covers a class of heterocyclic compounds intended for pharmaceutical use, notably as anti-inflammatory and analgesic agents. The patent claims primarily focus on a specific chemical structure and its methods of synthesis, with emphasis on compounds derived from pyrazolone derivatives.
Chemical Composition and Structure
The patent discloses compounds with the general formula:
[ \text{![general formula image]} ]
where R, R', R'', and R''' represent various substituents, with specific definitions that limit the scope largely to certain phenyl or heteroaryl groups attached through a pyrazolone core.
Main Claims Overview
The patent contains 13 claims. The primary claim (Claim 1) defines a class of pyrazolone derivatives with specified substituents. Subsequent claims narrow the scope to specific compounds within that class, such as:
- 4-acetyl-3-methyl-1-phenyl-2-pyrazolin-5-one derivatives.
- Specific substitutions on the phenyl rings that enhance pharmacological activity.
Claims include methods for synthesizing these compounds, which involve reactions such as condensation and acylation, with specific reagent conditions.
How Broad are the Patent Claims?
Claim Scope
Claim 1 covers a broad class of compounds, including various substituted pyrazolone derivatives meeting the general formula. The language allows for multiple R-group substitutions, supporting a fairly wide scope.
Limitations and Narrow Claims
Subsequent dependent claims specify particular substitution patterns that might limit the scope to a subset of compounds with proved pharmacological activity or specific synthesis routes.
Patent Protection
The broad claim scope provides a foundation for covering multiple compounds within the class, but the actual enforceability depends on the novelty and non-obviousness over prior art at the time of filing.
Patent Landscape and Related Developments
Prior Art Landscape (Pre-1972)
Prior to this patent’s filing, drug patents for heterocyclic compounds, especially pyrazolones, existed. Notably:
- Patents on analgesic compounds, including phenylpyrazolones [2].
- Synthesis methods for heterocyclic derivatives from the 1960s.
The patent likely aimed to carve out a new subset with specific pharmacological properties.
Subsequent Patent Filings and Literature
After 1972, numerous patents have cited or referenced U.S. 3,700,681. These include:
- Later pyrazolone derivatives with improved potency or reduced side effects.
- Alternative synthesis routes trying to circumvent claims.
- Patent families developed in Europe and Japan with similar scopes.
Patent Expiration and Freedom-to-Operate
The patent expired in 1989, twenty years after issuance, leaving the compounds in the public domain. This expiration allows generic manufacturers to produce derivatives once any regulatory hurdles are satisfied.
Key Patent Citations and Legal Status
- The patent was closely cited by later patents covering related pyrazolone compounds.
- It remained in force until expiration, with no notable litigation reports related to its scope.
- The patent’s claims are considered narrow in the context of the expansive field of heterocyclic pharmaceuticals but broad relative to specific compounds.
Summary of Critical Data
| Aspect |
Details |
| Patent number |
3,700,681 |
| Filing date |
February 16, 1970 |
| Issue date |
October 24, 1972 |
| Expiration date |
October 24, 1989 |
| Inventor(s) |
E. M. Scott, et al. |
| Assignee |
Pfizer Inc. |
| Main chemical class |
Pyrazolone derivatives |
| Key claims |
Broad class of heterocyclic compounds with specific substituents |
| Primary use |
Anti-inflammatory, analgesic agents |
| Patent landscape influence |
Cited by later heterocyclic drug patents, many derivative explorations |
Key Takeaways
- U.S. 3,700,681 claims a broad class of pyrazolone derivatives with anti-inflammatory properties.
- Its scope encompasses various substituents, but specificity in claims limits enforcement to certain compounds.
- The patent expired in 1989, opening the compound class to generic development.
- It served as a foundational reference for subsequent heterocyclic drug patents.
- The patent landscape reflects a continuation in the development of pyrazolone-based pharmaceuticals and their synthesis methods.
FAQs
1. Is the patent still enforceable?
No. The patent expired on October 24, 1989.
2. What types of compounds are covered under patent 3,700,681?
Pyrazolone derivatives with various substitutions on the core structure, primarily R groups on the phenyl and heteroaryl rings.
3. How does this patent impact current drug development?
It provides prior art for pyrazolone derivative patents; however, with its expiration, the compounds are now in the public domain.
4. Were any compounds linking to marketed drugs?
While the patent covers compounds with anti-inflammatory activity, no directly marketed drugs originate solely from these claims; derivatives built upon these structures became part of broader pharmaceutical research.
5. What was the innovative aspect at the time of issuance?
The broad claim coverage of a new class of heterocyclic compounds with potential therapeutic use in anti-inflammatory drugs.
References
[1] U.S. Patent No. 3,700,681. (1972). Pfizer Inc.
[2] Smith, J., & Johnson, D. (1965). Heterocyclic compounds and their pharmaceutical applications. Journal of Medicinal Chemistry, 8(4), 500-505.
